TC BioPharm Limited Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Cover
- Cover
Financial Statements
Notes to Financial Statements
Accounting Policies
- Accounting policies (Policies)
Notes Tables
Notes Details

Income tax credit

Income tax credit	6 Months Ended
Jun. 30, 2022
Major components of tax expense (income) [abstract]
Income tax credit	6. Income tax credit The income tax credit recognized primarily represents the U.K. research and development tax credit. In the United Kingdom, the Company is able to surrender some of its losses for a cash rebate of up to 33.35% of expenditure related to eligible research and development projects.

Income tax credit

6 Months Ended

Jun. 30, 2022

Major components of tax expense (income) [abstract]

Income tax credit

6. Income tax credit

The income tax credit recognized primarily represents the U.K. research and development tax credit. In the United Kingdom, the Company is able to surrender some of its losses for a cash rebate of up to 33.35% of expenditure related to eligible research and development projects.